Microbix Biosystems Inc T.MBX

Alternate Symbol(s): MBXBF

Healthcare Biotechnology

Microbix Biosystems Inc. develops and commercializes biological and technological solutions for human health and wellbeing. It enables the commercialization of diagnostic assays by making a range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Its segments include development, manufacturing and sales of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows and viral transport medium to enable collection of patient test samples and, and development and commercialization of novel and proprietary products or technologies, such as Kinlytic. Its Kinlytic urokinase is a biologic thrombolytic drug used to treat blood clots.

TSX:MBX - Post by User

Microbix Biosystems Inc > 4th Quarter

<< Previous

Bullboard Posts

Next >>

Comment by rjc7on Feb 21, 2021 6:36pm

137 Views

Post# 32622968

RE:RE:RE:4th Quarter

Paid research or not, they still have to work with real numbers and drill down on every scenario an investor would need to see to make an informed decision as to whether they will invest or not. This particular report hit all the hot buttons, and nothing pertinent showed any negative concerns or worries going forward.

<< Previous

Bullboard Posts

Next >>

What will the U.S. election results mean for Canada?